Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies
The Journal of Immunology · 2023
DOI: 10.4049/jimmunol.2300315 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Immunology, 2023. Verfasst von John P Evans und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Retrovirus Research, The Ohio State University, Columbus, OH. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 103 Literaturangaben. Gefördert von: National Cancer Institute, National Institutes of Health, The Ohio State University, Distinguished University Fellowship, The Ohio State University, A Private Donor’s Gift.
Abstract (Originalsprache)
The impacts of the COVID-19 pandemic led to the development of several effective SARS-CoV-2 vaccines. However, waning vaccine efficacy as well as the antigenic drift of SARS-CoV-2 variants has diminished vaccine efficacy against SARS-CoV-2 infection and may threaten public health. Increasing interest has been given to the development of a next generation of SARS-CoV-2 vaccines with increased breadth and effectiveness against SARS-CoV-2 infection. In this Brief Review, we discuss recent work on the development of these next-generation vaccines and on the nature of the immune response to SARS-CoV-2. We examine recent work to develop pan-coronavirus vaccines as well as to develop mucosal vaccines. We further discuss challenges associated with the development of novel vaccines including the need to overcome “original antigenic sin” and highlight areas requiring further investigation. We place this work in the context of SARS-CoV-2 evolution to inform how the implementation of future vaccine platforms may impact human health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Retrovirus Research, The Ohio State University, Columbus, OH.
- Department of Veterinary Biosciences, The Ohio State University, Columbus, OH.
- Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, OH.
- Viruses and Emerging Pathogens Program, Infectious Diseases Institute, The Ohio State University, Columbus, OH.
- Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH.
ORCID-Profile: Shan-Lu Liu
Förderung
- National Cancer Institute, National Institutes of Health
- The Ohio State University, Distinguished University Fellowship
- The Ohio State University, A Private Donor’s Gift
Zitieren
APA
Evans, J. P., & Liu, S. L. (2023). Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300315
Vancouver
Evans JP, Liu SL. Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2300315
BibTeX
@article{Evans2023,
author = {Evans, John P and Liu, Shan-Lu},
title = {Challenges and Prospects in Developing Future SARS-CoV-2 Vaccines: Overcoming Original Antigenic Sin and Inducing Broadly Neutralizing Antibodies},
journal = {The Journal of Immunology},
year = {2023},
doi = {10.4049/jimmunol.2300315}
}
EUVIMED